The FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL. The U.S. Food and Drug Administration (FDA) recentlyapproved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating certain...
Treatment approved for the treatment of adults with two types of acute myeloid leukemia that have particularly poor prognoses.
Enasidenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months. The U.S. Food and Drug Administration (FDA) recentlyapproved the molecularly targeted therapeutic enasidenib (Idhifa) for treating certain...
The FDA expanded the use of the immunotherapy nivolumab to include the treatment of certain patients with colorectal cancer.
The FDA approved the first of a new class of immunotherapy known as CAR T-cell therapy for treating patients with acute lymphoblastic leukemia.
The FDA approved a molecularly targeted therapeutic for treating certain patients with HER2-positive breast cancer.
The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer. The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab (Keytruda) for the treatment of certain...
The FDA approved the first cancer treatment for use based on the tumor having certain biomarkers and not where in the body the tumor originated.
The FDA approved an immune checkpoint inhibitor – a type of immunotherapy – to treat certain patients with bladder cancer.
The FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More